Diaceutics PLC
Simbols: DIUXF
PNK
1.3672
USDTirgus cena šodien
-124.8659
P/E koeficients
2.7906
PEG koeficients
123.70M
MRK Cap
- 0.00%
DIV ienesīgums
Diaceutics PLC (DIUXF) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 19.8 | 19.7 | 25.3 | |||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.net-receivables | 0 | 10.4 | 10 | 7.8 | |||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.other-current-assets | 0 | 0.6 | 0.4 | 0.6 | |||||||
balance-sheet.row.total-current-assets | 0 | 30.9 | 30.1 | 33.6 | |||||||
balance-sheet.row.property-plant-equipment-net | 0 | 2.1 | 2.1 | 0.2 | |||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.intangible-assets | 0 | 15.2 | 12.8 | 9.4 | |||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 15.2 | 12.8 | 9.4 | |||||||
balance-sheet.row.long-term-investments | 0 | 17.1 | 14.7 | 9.2 | |||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0.3 | |||||||
balance-sheet.row.other-non-current-assets | 0 | -17.1 | -14.7 | -9.2 | |||||||
balance-sheet.row.total-non-current-assets | 0 | 17.4 | 15 | 9.9 | |||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-assets | 0 | 48.3 | 45 | 43.5 | |||||||
balance-sheet.row.account-payables | 0 | 0.8 | 0.5 | 0.5 | |||||||
balance-sheet.row.short-term-debt | 0 | 0.1 | 0.3 | 0.1 | |||||||
balance-sheet.row.tax-payables | 0 | 0.4 | 0.3 | 0.8 | |||||||
balance-sheet.row.long-term-debt-total | 0 | 1.2 | 1.3 | 0 | |||||||
Deferred Revenue Non Current | 0 | 0 | -0.4 | 0 | |||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||
balance-sheet.row.other-current-liab | 0 | 2.5 | 1.6 | 2 | |||||||
balance-sheet.row.total-non-current-liabilities | 0 | 2 | 1.7 | 0.4 | |||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.capital-lease-obligations | 0 | 1.3 | 1.4 | 0 | |||||||
balance-sheet.row.total-liab | 0 | 5.7 | 4.4 | 3.3 | |||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0.3 | 0 | |||||||
balance-sheet.row.common-stock | 0 | 0.2 | 0.2 | 0.2 | |||||||
balance-sheet.row.retained-earnings | 0 | 5.3 | 4.1 | 3.2 | |||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0.1 | -0.3 | 0 | |||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 36.9 | 36.4 | 36.9 | |||||||
balance-sheet.row.total-stockholders-equity | 0 | 42.5 | 40.6 | 40.2 | |||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 48.3 | 45 | 43.5 | |||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-equity | 0 | 42.5 | 40.6 | 40.2 | |||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||
Total Investments | 0 | 17.1 | 14.7 | 9.2 | |||||||
balance-sheet.row.total-debt | 0 | 1.3 | 1.6 | 0.1 | |||||||
balance-sheet.row.net-debt | 0 | -18.5 | -18.1 | -25.1 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 0.6 | 0.5 | -0.7 | |||||||
cash-flows.row.depreciation-and-amortization | 0 | 3 | 1.8 | 0.8 | |||||||
cash-flows.row.deferred-income-tax | 0 | 1.3 | -0.5 | -0.7 | |||||||
cash-flows.row.stock-based-compensation | 0 | 0.5 | 0.4 | 0.3 | |||||||
cash-flows.row.change-in-working-capital | 0 | -0.3 | -1.7 | 0.5 | |||||||
cash-flows.row.account-receivables | 0 | -1.6 | -1.5 | 0.5 | |||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.account-payables | 0 | 1.3 | -0.2 | -0.1 | |||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.other-non-cash-items | 0 | 0 | 0.1 | 0 | |||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -4.9 | -5.6 | -6.3 | |||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.other-investing-activites | 0 | 0.1 | 0 | 0 | |||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -4.8 | -5.6 | -6.3 | |||||||
cash-flows.row.debt-repayment | 0 | 0 | -0.1 | 0 | |||||||
cash-flows.row.common-stock-issued | 0 | 0.1 | 0 | 19.6 | |||||||
cash-flows.row.common-stock-repurchased | 0 | -0.1 | -0.2 | 0 | |||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.other-financing-activites | 0 | -0.2 | 0 | 0 | |||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -0.2 | -0.3 | 19.6 | |||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | -0.3 | 0 | |||||||
cash-flows.row.net-change-in-cash | 0 | 0.2 | -5.6 | 13.5 | |||||||
cash-flows.row.cash-at-end-of-period | 0 | 19.8 | 19.7 | 25.3 | |||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 19.7 | 25.3 | 11.7 | |||||||
cash-flows.row.operating-cash-flow | 0 | 5.1 | 0.6 | 0.3 | |||||||
cash-flows.row.capital-expenditure | 0 | -4.9 | -5.6 | -6.3 | |||||||
cash-flows.row.free-cash-flow | 0 | 0.2 | -5 | -6 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 19.5 | 13.9 | 12.7 | |||||||
income-statement-row.row.cost-of-revenue | 0 | 2.8 | 3.2 | 3.2 | |||||||
income-statement-row.row.gross-profit | 0 | 16.7 | 10.7 | 9.5 | |||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.operating-expenses | 0 | 16.2 | 10.2 | 9.7 | |||||||
income-statement-row.row.cost-and-expenses | 0 | 18.9 | 13.4 | 13 | |||||||
income-statement-row.row.interest-income | 0 | 0.1 | 0.1 | 0 | |||||||
income-statement-row.row.interest-expense | 0 | 0.1 | 0.1 | 0 | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.total-other-income-expensenet | 0 | 0 | -0.1 | 0 | |||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.total-operating-expenses | 0 | 0 | -0.1 | 0 | |||||||
income-statement-row.row.interest-expense | 0 | 0.1 | 0.1 | 0 | |||||||
income-statement-row.row.depreciation-and-amortization | 0 | 3 | 1.8 | 0.8 | |||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||
income-statement-row.row.operating-income | 0 | 0.6 | 0.6 | -0.7 | |||||||
income-statement-row.row.income-before-tax | 0 | 0.6 | 0.5 | -0.7 | |||||||
income-statement-row.row.income-tax-expense | 0 | -0.2 | -0.1 | -0.9 | |||||||
income-statement-row.row.net-income | 0 | 0.7 | 0.6 | 0.3 |
Biežāk uzdotie jautājumi
Kas ir Diaceutics PLC (DIUXF) kopējie aktīvi?
Diaceutics PLC (DIUXF) kopējie aktīvi ir 48256000.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir N/A.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.796.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir -0.027.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir -0.027.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir -0.061.
Kāda ir Diaceutics PLC (DIUXF) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir 724000.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 1329000.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 16166000.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 0.000.